Literature DB >> 8719525

Myxoma virus as a vaccine vector for rabbits: antibody levels to influenza virus haemagglutinin presented by a recombinant myxoma virus.

P J Kerr1, R J Jackson.   

Abstract

To determine whether myxoma virus (MV) could be used as a vector for antigen presentation to European rabbits (Oryctolagus cuniculus), despite its immunosuppressive properties, a recombinant MV expressing the influenza virus haemagglutinin (HA) was constructed. Domestic rabbits, inoculated with the recombinant virus, developed high plasma antibody titres to the HA and IgG to HA was also detected in vaginal secretions. Antibody titres to HA obtained with recombinant MV were similar to titres obtained in rabbits inoculated with vaccinia virus expressing the HA. These results indicate that MV is an efficient vector for antigen presentation in rabbits.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8719525     DOI: 10.1016/0264-410x(95)00113-f

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus.

Authors:  J Bárcena; M Morales; B Vázquez; J A Boga; F Parra; J Lucientes; A Pagès-Manté; J M Sánchez-Vizcaíno; R Blasco; J M Torres
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  Myxoma virus encodes an alpha2,3-sialyltransferase that enhances virulence.

Authors:  R J Jackson; D F Hall; P J Kerr
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 3.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

Review 4.  Viral vectors for veterinary vaccines.

Authors:  M Sheppard
Journal:  Adv Vet Med       Date:  1999

Review 5.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.